Endothelial Dysfunction: Mechanisms, Cardiovascular Risk, and Assessment

The endothelium is a dynamic interface regulating vascular tone, inflammation, thrombosis, and angiogenesis through mediators like nitric oxide (NO), prostacyclin, and endothelin-1. Endothelial dysfunction—characterized by impaired NO bioavailability—is an early, reversible step toward atherosclerosis.

Pathophysiological Hallmarks

  1. Impaired vasodilation – Reduced NO leads to vasoconstriction and increased vascular resistance.
  2. Pro-inflammatory state – Upregulation of adhesion molecules (VCAM-1, ICAM-1) and cytokines.
  3. Oxidative stress – Reactive oxygen species scavenge NO; uncoupled eNOS produces superoxide.
  4. Pro-thrombotic shift – Decreased thrombomodulin, increased PAI-1 and von Willebrand factor.
  5. Impaired angiogenesis – Inadequate collateral formation in ischemic tissues.

Major Risk Factors

  • Hypertension, dyslipidemia, diabetes, smoking, obesity, sedentary lifestyle, aging.

Clinical Assessment

  • Flow-mediated dilation (FMD) of the brachial artery – gold standard research tool.
  • Peripheral arterial tonometry (EndoPAT) – operator-independent alternative.
  • Biomarkers: ADMA, endothelin-1, von Willebrand factor.

Therapeutic Targets

Lifestyle interventions (exercise, Mediterranean diet), statins, ACE inhibitors/ARBs, SGLT2 inhibitors, and GLP-1 agonists all improve endothelial function, reducing cardiovascular risk.

Cardiovascular Disease - Related Articles